Clinical Trial Update: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating rituximab to prevent acute graft-versus-host disease in donor stem cell transplantation for hematologic cancers; study terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Cancer

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Nebraska | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Status: TERMINATED | Results posted: 2019-02-26